USA flag logo/image

An Official Website of the United States Government

Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96376
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL104948
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
CHANTEST, INC.
14656 NEO PKY CLEVELAND, OH -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car
Agency: HHS
Contract: 1R43HL104948-01
Award Amount: $149,275.00
 

Abstract:

DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently characterized a population of SC-hCMs that will be made commer cially available in 2010 by our collaborator GE Healthcare, and have demonstrated that these cells show sensitive pharmacology that accurately predicts clinical responses. However, the utility of SC-hCMs in cardiac safety testing, and more broadly, in rege nerative medicine, is partially limited by the fact that they are functionally immature. The resting and action potential properties of the cells resemble embryonic or neonatal CMs rather than adult CMs, and SC-hCMs spontaneously beat in culture which limi ts their utility for detection of rate-dependent compound effects. To address these shortcomings, we propose to genetically engineer functionally mature SC-hCMs by selectively supplementing under- expressed ionic currents. The functionally mature SC-hCMs w ill then be validated for use in improved commercial cardiac safety screens. More broadly, these experiments will serve a proof-of-concept function by identifying ion channels that are under-expressed in terminally differentiated SC-hCMs. Once these ion ch annels are identified, future experiments may focus on inducing stable, elevated ion channel expression early in the differentiation process. PUBLIC HEALTH RELEVANCE: The recent availability of human myocytes derived from stem cells (SC-hCMs) provid es an opportunity to develop pre-clinical cardiac safety assays with better predictive value compared to conventional assays. The benefits to public health are: 1) Improved predictivity in pre-clinical cardiac safety screening, thereby reducing risk of adv erse cardiac events in clinical trials 2) Added cost-efficiencies in the pharmaceutical drug development process, and 3) Long-term potential to increase the utility of SC-hCMs in the field of regenerative medicine.

Principal Investigator:

Andrew H. Brueningwright
5034947732
BRUENING@OHSU.EDU

Business Contact:

Arthur M. Brown
ABROWN@CHANTEST.COM
Small Business Information at Submission:

CHANTEST, INC.
CHANTEST CORPORATION 14656 NEO PKY CLEVELAND, OH 44128

EIN/Tax ID: 120867531
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No